Navigation Links
VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
Date:5/13/2009

Enrollment in First Pivotal Phase 3 Avanafil Study REVIVE (TA-301) is Complete

MOUNTAIN VIEW, Calif., May 13 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, today announced that it has initiated an open label safety study (TA-314) with its investigational drug, avanafil, in males with erectile dysfunction (ED).

VIVUS also announced today that it has completed enrollment in REVIVE (TA-301), a randomized, double-blind, placebo-controlled phase 3 study of avanafil in men with a history of generalized ED and the first of several planned phase 3 studies of avanafil. Approximately 650 patients have been enrolled in the study. Top-line results of REVIVE are expected in the fourth quarter of 2009.

Avanafil, a next-generation, fast-acting, selective, oral, phosphodiesterase type 5 (PDE5) inhibitor, is VIVUS' investigational product for the treatment of ED. The phase 3 program for avanafil is funded through a $30 million collaboration with Deerfield Management.

"We continue to make excellent progress on the avanafil phase 3 program, and are pleased with the rapid rate at which we accrued patients in our first pivotal study, REVIVE," commented Charles Bowden, MD, senior director of clinical development at VIVUS. "Initiation of the TA-314 safety study is a critical step in advancing avanafil toward an NDA filing. We are confident that avanafil will provide a much needed new option for the millions of men living with ED, and we look forward to announcing data from both of these studies later this year and next."

The open-label study is being conducted in approximately 600 patients across 40 U.S. centers. Patients completing either the 12-week REVIVE or R
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
4. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
5. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
6. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
7. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
8. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
9. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
10. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
11. Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... According to a new market research report ... Display, & Microprocessor/MCU), by Application (Imaging, Medical Therapeutics, Diagnosis, ... Global Forecast to 2020", published by MarketsandMarkets, the total ... $56.50 Billion by 2020, growing at a CAGR of ... market data Tables and 71 Figures spread through 312 ...
(Date:9/17/2014)... , Sept. 17, 2014 An analysis ... regarding patients taking Sovaldi® (sofosbuvir), a new and expensive ... shows that over the last several months (May through ... downward trend in Sovaldi utilization. This suggests another surge ... new therapeutic regimens of similar efficacy and shorter duration ...
(Date:9/17/2014)... MORRISTOWN, N.J. , Sept. 17, 2014 /PRNewswire/ ... LLP (MDM&C), today announced that it will serve ... the Benefits and Avoiding the Risks of Healthcare ... 2014 that will examine delivery systems, reimbursement, compliance ... Affordable Care Act. Logo -  ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2
... Members and Staff Will Focus on Advances in ... Research and Treatment of Lung Cancer in Women, SEATTLE, ... with the Society for Women,s Health,Research, the Lung Cancer Alliance ... Female Matters to Research," on,Capitol Hill to discuss advances in ...
... results outline dabigatran etexilate as potential thromboprophylaxis ... hip replacement surgery, RIDGEFIELD, Conn., Sept. 13 ... issue of The Lancet will publish results,from the ... therapy for patients undergoing total hip replacement surgery(1).,The ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill 2Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill 3The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor 2The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor 3
(Date:9/17/2014)... The National Resident Matching Program has published ... of the relationship between unique applicant characteristics and success ... edition is based on the 2014 Main Residency Match ... school senior students and all other applicants. , ... new edition of Charting Outcomes in the Match,” said ...
(Date:9/17/2014)... 18, 2014 ADVOCATE, the premier ... announces today that they have been awarded the ... in Fort Wayne, Indiana. , ADVOCATE ... encompassing their proprietary suite of billing process software ... improves radiology billing and data quality consistency by ...
(Date:9/17/2014)... 2014 According to an August ... titled “Adverse Events Associated with Use of Enhancement ... unapproved use of Expression, a hyaluronic acid product, ... reactions including discoloration, lumps, bruising, nodules, and swelling. ... for cosmetic use include Restylane , Juvéderm, ...
(Date:9/17/2014)... 17, 2014 As kinship care continues ... who cannot live with their parents, emphasis on kinship ... to enhance services and supports for kinship caregivers and ... National Kinship Care Conference is being held this week ... best practice, policy, program and service development for kinship ...
(Date:9/17/2014)... 17, 2014 Sunday night saw ... and ushered in a new national spokesperson for ... America Organization’s official national platform, Children’s Miracle ... newest National Goodwill Ambassador. , Kazantsev’s year in ... Network Hospitals across the U.S., visiting with patients ...
Breaking Medicine News(10 mins):Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 3Health News:ADVOCATE Wins Radiology Billing Agreements with Fort Wayne Radiology 2Health News:ADVOCATE Wins Radiology Billing Agreements with Fort Wayne Radiology 3Health News:Simon Ourian, Kim Kardashian's Cosmetic Surgeon, Warns About Illegal Use of Expression as a Dermal Filler 2Health News:Arizona’s Children Association Kinship Service Providers Invited to Present at the CWLA National Conference 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 3
... July 9, 2009 The President of the ... statement today on President Obama,s nomination of Francis Collins, M.D., ... Health (NIH):,"At no other time in recent memory has there ... in the power of science to deliver solutions to the ...
... Bioheart, Inc. (OTC Bulletin Board: BHRT) (the "Company") ... July 7, 2009, Bioheart, Inc. (the "Company") has received proceeds ... common stock and warrants under its current offering under Regulation ... Common Stock to be issued in connection with the Offering ...
... Parsippany took top honors in the state,s first-ever 100-day ... on June 2nd. With participating residents losing an average of ... pounds, Parsippany was presented with a plaque and Morris County ... , Residents throughout northern and central New Jersey also participated ...
... , ... and Directory Helps Attendees and Exhibitors,Connect at AAMSE Conference and Beyond. , ... Arlington, VA (PRWEB) July 9, 2009 -- MarketArt ... enhanced attendee experience at the American Association of Medical Society Executives (AAMSE) 2009 ...
... Institute of Technology (Caltech) and the Scripps Research Institute have ... chemicals that have the potential to take the place of ... James R. Heath, the Elizabeth W. Gilloon Professor and ... M. Keck Professor of Chemistry at the Scripps Research Institute ...
... United States Senate Committee on Small Business ... Member Olympia J. Snowe, R-Maine, today convened a ... relate to small businesses. Participants at the roundtable, ... the Perspective of Small Businesses," included U.S. Sen. ...
Cached Medicine News:Health News:Bioheart, Inc. Announces Receipt of $2.8 Million in Proceeds From Pipe Financing 2Health News:Bioheart, Inc. Announces Receipt of $2.8 Million in Proceeds From Pipe Financing 3Health News:Parsippany Takes Top Honors in New Jersey's First-Ever Toxic Waistlines Contest 2Health News:Parsippany Takes Top Honors in New Jersey's First-Ever Toxic Waistlines Contest 3Health News:MarketArt to Enhance Attendee Experience at AAMSE Annual Conference 2Health News:MarketArt to Enhance Attendee Experience at AAMSE Annual Conference 3Health News:Caltech chemists say antibody surrogates are just a 'click' away 2Health News:Caltech chemists say antibody surrogates are just a 'click' away 3Health News:Landrieu, Snowe Convene Roundtable on Healthcare for Small Businesses 2Health News:Landrieu, Snowe Convene Roundtable on Healthcare for Small Businesses 3
... The Venus-i Laser System is a ... laser system with applications in dermatology, cosmetic ... ophthalmology. An ideal laser for skin resurfacing, ... most powerful, Erbium:YAG lasers on the market. ...
... Laser System is a new, portable, light ... applications in dermatology, cosmetic and plastic surgery, ... laser for skin resurfacing, it is the ... lasers on the market. It provides an ...
... biolitecs Ceralas D 980 nm diode ... clean, bloodless field for most surgical procedures. ... D cuts optically without collateral tissue ... laser coagulates blood instantly and seals small ...
... The APTIMA COMBO 2 Assay is ... that uses target capture for in vitro ... CT and GC. The assay uses a ... capture (TC), Transcription-Mediated Amplification (TMA) and Dual ...
Medicine Products: